| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Mineralys Therapeutics, Inc. (MLYS) has 8 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. MLYS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.90M | $233.48M | - | |
| Dir | 5.46M | $161.19M | - | |
| CEO | 689.3K | $20.36M | -15,730 | |
| Dir | 588.2K | $17.38M | - | |
| Other | 69.8K | $2.06M | -20,822 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | Ra Capital Management, L.P.52 | Director | Buy | 1,250,000 | $16.00 | $20,000,000.00 | +64.8% | -10.1% | -19.3% |